Efficient and knowledgeable biostatistical support is crucial to the proper design and interpretation of research in the biomedical sciences. The principal objective of the Biostatistics Core will be to provide project investigators a centralized resource for statistical expertise. Statistical issues will be addressed at all levels of investigation: from the design of experiments, to the maintenance of data quality, and to the description and inferential statements made from the collected data. In support of this objective, the specific aims of the Biostatistics Core include: 1. To collaborate with project investigators in the formulation of hypotheses and the design of experimental studies 2. To conduct and direct the statistical analysis of data generated by project investigators including both descriptive summary statistics as well as more sophisticated inferential procedures 3. To provide assistance in developing and implementing data management systems to allow investigators to effectively and efficiently manage and analyze their data 4. To coordinate the development of new statistical methodologies, when needed, to directly support research issues that may arise as part of the current Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA101956-05
Application #
8117630
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$184,346
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Byrd, John C; Furman, Richard R; Coutre, Steven E et al. (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125:2497-506
Lucas, David M; Ruppert, Amy S; Lozanski, Gerard et al. (2015) Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr Leuk Lymphoma 56:3031-7
Blachly, James S; Ruppert, Amy S; Zhao, Weiqiang et al. (2015) Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 112:4322-7
Flynn, J; Jones, J; Johnson, A J et al. (2015) Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29:1524-9
Motiwala, T; Kutay, H; Zanesi, N et al. (2015) PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model. Leukemia 29:1350-9
Claus, Rainer; Lucas, David M; Ruppert, Amy S et al. (2014) Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 124:42-8
Dong, Shuai; Guinn, Daphne; Dubovsky, Jason A et al. (2014) IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124:3583-6
Kohrt, Holbrook E; Sagiv-Barfi, Idit; Rafiq, Sarwish et al. (2014) Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 123:1957-60
Wei, Quan-Xiang; Claus, Rainer; Hielscher, Thomas et al. (2013) Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia. PLoS One 8:e55261
Singh, Rajbir; Mortazavi, Amir; Telu, Kelly H et al. (2013) Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis. Nucleic Acids Res 41:9284-95

Showing the most recent 10 out of 73 publications